BioLineRx (BLRX) Total Current Liabilities (2011 - 2026)

BioLineRx's Total Current Liabilities history runs 15 years deep, the most recent figure standing at $12.1 million for Q4 2025.

• In Q4 2025, Total Current Liabilities fell 21.31% year-over-year to $12.1 million; the TTM figure through Dec 2025 stood at $12.1 million (down 21.31% YoY), while the FY2025 annual figure was $12.1 million, down 21.31% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $12.1 million, down from $13.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $42.8 million in Q4 2023, with the low at $8.1 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $12.3 million (2023), against an average of $15.9 million.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 300.64% in 2023, then slumped 63.99% in 2024.
• BioLineRx's Total Current Liabilities stood at $9.7 million in 2021, then rose by 9.88% to $10.7 million in 2022, then jumped by 300.64% to $42.8 million in 2023, then plunged by 63.99% to $15.4 million in 2024, then retreated by 21.31% to $12.1 million in 2025.
• Business Quant data shows BLRX's Total Current Liabilities at $12.1 million in Q4 2025, $13.7 million in Q3 2025, and $15.5 million in Q2 2025.